【ChiCTR-TRC-10000902】A randomized controlled trial comparing the treatment effects of patching versus acupuncture plus patching on amblyopia in patients of 7 to <13 years old

查看原文

立即下载

基本信息

登记号

ChiCTR-TRC-10000902

试验状态

结束

药物名称

药物类型

规范名称

首次公示信息日的期

2010-05-13

临床申请受理号

靶点

适应症

Amblyopia

试验通俗题目

A randomized controlled trial comparing the treatment effects of patching versus acupuncture plus patching on amblyopia in patients of 7 to <13 years old

试验专业题目

A randomized controlled trial comparing the treatment effects of patching versus acupuncture plus patching on amblyopia in patients of 7 to <13 years old

申办单位信息

申请人联系人

请登录查看

申请人名称

请登录查看

联系人邮箱

请登录查看

联系人邮编

联系人通讯地址

请登录查看

临床试验信息

试验目的

To assess the effects of patching versus acupuncture plus patching on amblyopia in patients of 7 to <13 years old

试验分类

请登录查看

试验类型

随机平行对照

试验分期

Ⅰ期

随机化

Random, active control, parallel groups

盲法

Single-blind

试验项目经费来源

Yan Ai Eye Foundation, DOVS, Hong Kong, China.

试验范围

目标入组人数

150;50

实际入组人数

第一例入组时间

2010-05-15

试验终止时间

2013-05-31

是否属于一致性

入选标准

1. Age: 7 to <13; 2. Amblyopia associated with strabismus (concomitant or inconcomitant), anisometropia, or both a. Criteria for strabismus: At least one of the following criteria must be met: (1) Heterotropia at distance and/or near fixation on examination (with or without spectacles); (2) History of strabismus surgery (or botulinum); (3) Documented history of strabismus which is no longer present (which in the judgment of the investigator could have caused amblyopia). b. Criteria for anisometropia: At least one of the following criteria must be met: (1) >0.50 D difference between eyes in spherical equivalent; (2) >1.50 D difference between eyes in astigmatism in any meridian; c. Criteria for combined mechanism amblyopia: Both of the following criteria must be met: (1) Criteria for strabismus are met (see above); (2) >1.00 D difference between eyes in spherical equivalent OR >1.50 D difference between eyes in astigmatism in any meridian. Note: the spherical equivalent requirement differs from that in the definition for refractive/anisometropic amblyopia. 3. Visual acuity, measured in each eye without cycloplegia within 7 days prior to randomization using the E-ETDRS protocol on Electronic Visual Acuity Tester, as follows: (1) Visual acuity in the amblyopic eye between 19 to 71 letters inclusive (20/40 to 20/400 inclusive); (2) Visual acuity in the sound eye >=79 letters (20/25 or better); (3) Interocular acuity difference >=10 letters (i.e., amblyopic eye acuity at least 2 lines worse than sound eye acuity). 4. No amblyopia treatment (other than spectacles) in the last 6 months (any treatment more than 6 months prior to enrollment is acceptable); 5. No current vision therapy or orthoptics; 6. Ocular examination within 6 months prior to enrollment showing no ocular cause for reduced visual acuity; 7. Cycloplegic refraction within 6 months prior to enrollment; 8. Myopia no more than -6.0 D spherical equivalent in either eye; 9. Spectacle correction for measurement of enrollment visual acuity must meet the following criteria and be based on a cycloplegic refraction that is no more than 6 months old (refractive error must be corrected with spectacles and not contact lenses): a. Requirements for spectacle correction: (1) For patients meeting criteria for strabismus (see 2.a above); (2) Hypermetropia if corrected must not be undercorrected by more than +1.50 D spherical equivalent, and the reduction in plus sphere must be symmetric in the two eyes. Otherwise, spectacle correction is at investigator discretion; (3) For patients meeting criteria for anisometropia or combined-mechanism (see #2. b, c above); (4) Spherical equivalent must be within 0.50 D of fully correcting the anisometropia; (5) Hypermetropia must not be undercorrected by more than +1.50 D spherical equivalent, and reduction in plus must be symmetric in the two eyes; (6) Cylinder power in both eyes must be within 0.50 D of fully correcting the astigmatism; (7) Cylinder axis in the spectacle lenses in both eyes must be within 6 degrees of the axis of the cycloplegic refraction when cylinder power is > 1.00 D. b. Spectacles meeting above criteria must be worn either: (1) for at least 16 weeks immediately prior to enrollment; or (2) until visual acuity in amblyopic eye is stable (defined as two consecutive visual acuity measurements by the same testing method at least 4 weeks apart with no improvement of one logMAR line or more); (3) An acuity measurement done any of the following ways may be considered the first of two consecutive measurements: 1) in current glasses; 2) in trial frames with full correction of hypermetropia with cycloplegia; or 3) by having the patient return in new glasses for first measurement. The second acuity measure does not have to be made through the same prescription as the first, if the second measure is made through a more accurate prescription. Note: since this determination is a pre-study procedure, the method of measuring visual acuity is not mandated although E-ETDRS testing is preferred if done as part of usual care. 10. No prior intraocular or refractive surgery; 11. No known reaction to or development of systemic side effects (e.g., confused mental state, somnolence, skin flushing, exacerbation of asthma) with prior use of cycloplegics and no known skin allergy to patch or bandage adhesives; 12. Parent willing to accept randomized treatment, available for at least 6 months of follow-up, and willing to be contacted by DOVS staff; 13. Informed parental consent.；

排除标准

1. Patients with ocular diseases other than refractive error, strabismus (including microtropia) and amblyopia; 2. Systemic diseases that require chronic or regular intermittent medication (e.g. Down Syndrome, asthma, allergy, epilepsy and so on); 3. Allergy to cycloplegics; 4. Inability to attend follow-up assessment; 5. Inability to tolerate and cooperate with acupuncture procedure; 6. Myopia more than -6.0D SE in the amblyopic eye.；

研究者信息

研究负责人姓名

请登录查看

试验机构

Hong Kong Eye Hospital

研究负责人电话

请登录查看

研究负责人邮箱

请登录查看

研究负责人邮编

联系人通讯地址

请登录查看